Science Strikes Back: Longevity
With recent advancements in bio-informatics, epigenetic reprogramming, and DNA repair, we appear to be on the cusp of meaningfully improving lifespan and making those years healthier.
Our “Science Strikes Back” series introduces some of the most exciting, forward-leaning venture investment sectors in deep tech.
Our Deep Tech Fund co-invests alongside established deep tech venture firms in companies taking on the toughest and potentially most lucrative technological challenges. Our point of view is that the need has never been higher for scientific thought and innovations tackling hard problems. Click below if you want to be notified when the fund opens in July 2020.
Deep Tech Focus #2 – Longevity
Defining the Space
Longevity and healthy living tech are naturally of immense interest to most people — perhaps more so than ever because of recent developments. Remarkably, we appear to be on the cusp of meaningfully improving lifespan and making those years healthier. Work in bio-informatics, epigenetic reprogramming, and DNA repair coming out of The Sinclair Lab at HMS and elsewhere hold great promise for slowing and repairing the impacts of aging.
To understand the scope of the opportunity, consider a few stats:
- Of all people who have ever lived past 65 in the entire history of the world, 2/3 are alive today.
- The population of those 60+ more than doubled from 1980 to 2017 to 962M. By 2100, that number is expected to hit 3.1B.
In Our Portfolio
AVG Portfolio Companies in the Extended Reality Space
These are just a few of our portfolio companies advancing the tech of longevity.
- Allevi is a developer of 3D bioprinters and bioinks intended to cure disease, test novel drugs, eliminate the organ waiting list, and build with life.
- Celularityis a developer of cellular therapies and biomaterials from the placenta to amplify the body’s ability to fight disease, heal, and regenerate itself.
- Unity Biotechnology is a developer of small molecule medicines that potentially halt, slow, or reverse age-associated diseases, while restoring human health.
AVG’s Deep Tech Fund invests in a venture portfolio of companies on the cutting edge of innovation. Our point of view is that the need has never been higher for scientific thought and innovations tackling hard problems. Do you want to be notified when the fund opens in July 2020? Click below.
Contact info@avgfunds.com for additional information. To see additional risk factors and investment considerations, visit avg-funds.com/Disclosures.